Imiquimod para Lentigo Maligno, frecuencia y cantidad de aplicaciones llevan a la adecuada resolución.

Both cumulative dose and treatment intensity affect tumor clearance, according to a study of 347 patients with lentigo maligna who were treated with imiquimod monotherapy. Researchers found:

• Histologic clearance rate was 76.2%.

• Clinical clearance rate was 78.3%.

• Incidence of clinical recurrence was 2.3% at a mean follow-up of 34.2 months.

• Treatment with > 60 total applications was associated with an odds ratio of 8.4 for histological clearance.

• Treatment with > 5 applications per week was associated with an odds ratio of 6.0 for histological clearance.

Citation: Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. [Published online ahead of print June 15, 2015]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2015.05.022.